GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Veru Inc (NAS:VERU) » Definitions » PS Ratio

Veru (VERU) PS Ratio : 8.91 (As of May. 04, 2024)


View and export this data going back to 1990. Start your Free Trial

What is Veru PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Veru's share price is $1.63. Veru's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.18. Hence, Veru's PS Ratio for today is 8.91.

Warning Sign:

Veru Inc stock PS Ratio (=8.96) is close to 1-year high of 8.96

The historical rank and industry rank for Veru's PS Ratio or its related term are showing as below:

VERU' s PS Ratio Range Over the Past 10 Years
Min: 1.02   Med: 4.93   Max: 31.11
Current: 8.93

During the past 13 years, Veru's highest PS Ratio was 31.11. The lowest was 1.02. And the median was 4.93.

VERU's PS Ratio is ranked better than
50.7% of 996 companies
in the Biotechnology industry
Industry Median: 9.035 vs VERU: 8.93

Veru's Revenue per Sharefor the three months ended in Dec. 2023 was $0.02. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.18.

Warning Sign:

Veru Inc revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of Veru was -47.10% per year. During the past 3 years, the average Revenue per Share Growth Rate was -33.00% per year. During the past 5 years, the average Revenue per Share Growth Rate was -5.80% per year. During the past 10 years, the average Revenue per Share Growth Rate was -10.60% per year.

During the past 13 years, Veru's highest 3-Year average Revenue per Share Growth Rate was 35.30% per year. The lowest was -54.00% per year. And the median was 0.70% per year.

Back to Basics: PS Ratio


Veru PS Ratio Historical Data

The historical data trend for Veru's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veru PS Ratio Chart

Veru Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.30 4.11 11.67 23.46 3.74

Veru Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.26 4.39 6.54 3.74 3.93

Competitive Comparison of Veru's PS Ratio

For the Biotechnology subindustry, Veru's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Veru's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Veru's PS Ratio distribution charts can be found below:

* The bar in red indicates where Veru's PS Ratio falls into.



Veru PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Veru's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=1.63/0.183
=8.91

Veru's Share Price of today is $1.63.
Veru's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.18.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Veru  (NAS:VERU) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Veru PS Ratio Related Terms

Thank you for viewing the detailed overview of Veru's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Veru (VERU) Business Description

Traded in Other Exchanges
Address
2916 North Miami Avenue, Suite 1000, Miami, FL, USA, 33127
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.
Executives
Mario Eisenberger director 515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
Lucy Lu director THE FEMALE HEALTH COMPANY, 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Harry Fisch director, 10 percent owner 515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
Grace Hyun director 48 NW 25TH STREET, SUITE 102, MIAMI FL 33127
Mitchell Shuster Steiner director, 10 percent owner, officer: President and CEO 175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103
K Gary Barnette officer: Chief Scientific Officer 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Michele Greco officer: VP and CFO 515 NORTH STATE STREET, SUITE 2225, CHICAGO IL 60654
Jesus Socorro director 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Todd Charles T Jr officer: CEO of FHC Division 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Michael L Rankowitz director 2500 LAKE COOK ROAD, RIVERWOODS IL 60015
Robert Getzenberg officer: Chief Scientific Officer 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Elgar Peerschke director 515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
Daniel Haines officer: CFO and COO 515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
David R Bethune director THE FEMALE HEALTH COMPANY, 515 NORTH STATE STREET, SUITE 2225, CHICAGO IL 60610
O B Parrish director, officer: Chairman/Chief Exec. Officer

Veru (VERU) Headlines

From GuruFocus